Genesis Therapeutics
Generative chemistry + ML for small-molecule design. Partnered with Genentech and Eli Lilly on multi-target programs.
- Location
- Burlingame, United States
- Raised
- $245M+
- Stage
- Series B
- Founded
- 2019
- Category
- Other
- Funding
- VC-backed
- Team
- 51-200
Funding figures as of Jul 2025 · not independently verified
Founders of Genesis Therapeutics
- Evan Feinberg
Investors backing Genesis Therapeutics
- Andreessen Horowitz
- Rock Springs Capital
Frequently asked questions
What does Genesis Therapeutics do?
Generative chemistry + ML for small-molecule design. Partnered with Genentech and Eli Lilly on multi-target programs.
Where is Genesis Therapeutics based?
Genesis Therapeutics is based in Burlingame, United States.
When was Genesis Therapeutics founded?
Genesis Therapeutics was founded in 2019.
How much has Genesis Therapeutics raised?
Genesis Therapeutics has raised $245M+ in their Series B round as of Jul 2025.
Who founded Genesis Therapeutics?
Genesis Therapeutics was founded by Evan Feinberg.
Who has invested in Genesis Therapeutics?
Genesis Therapeutics is backed by Andreessen Horowitz, Rock Springs Capital.
How Genesis Therapeutics would pitch themselves
○ Auto-generated01Target customer
The most challenging drug-discovery problems — the core audience Genesis Therapeutics's product is built around.
02Problem they solve
Generative chemistry + ML for small-molecule design. Partnered with Genentech and Eli Lilly on multi-target programs. The category has historically been served by tools that miss the modern workflow this product is built around.
03Key differentiator
Genesis Therapeutics differentiates on ai for the most challenging drug-discovery problems. Backed by Andreessen Horowitz + Rock Springs Capital, $245M+ raised — the company has resources + validation to compound this thesis. Founded by Evan Feinberg.
04Go-to-market strategy
Growth-stage GTM — multi-channel revenue motion (direct enterprise sales, channel partnerships, marketplace listings). Vertical specialisation + verticalised AE teams targeting enterprise + mid-market.